Study guide

Emergency contraception and abortion

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Emergency contraception and abortion

Key Takeaways Explain This Topic AI

A copper IUD is an effective emergency-contraception option and provides ongoing contraception.

After ulipristal, wait five days before starting progestogen-containing contraception.

Use seven further days of backup after restarting a combined pill following ulipristal.

Last updated: October 2026

Modalities and Clinical Selection

Copper Intrauterine Device (Cu-IUD) :

The Gold Standard : Efficacy exceeds 99.9% (failure rate < 0.1 % < 0.1\% < 0.1% ).

Timeframe : Can be inserted up to 120 hours (5 days) after UPSI, or up to 5 days after the earliest calculated day of ovulation.

Advantages : Independent of body weight or BMI; provides immediate, highly effective ongoing contraception for 5 to 10 years.

Ulipristal Acetate 30 mg oral (EllaOne) :

Timeframe : Licensed for oral administration up to 120 hours (5 days) post-UPSI.

Mechanism : A selective progesterone receptor modulator (SPRM). Binds with high affinity to progesterone receptors, delaying follicular development and postponing ovulation by at least 5 days, even after the luteinizing hormone (LH) surge has commenced (up until the LH peak).

Weight and oral EC: Higher weight/BMI may reduce effectiveness of oral EC, including ulipristal. A copper IUD is the most effective option and is not known to lose efficacy with body weight. Discuss timing, suitability and access without denying oral treatment when an IUD cannot be provided.

Further exposure: Oral EC does not protect later intercourse. Repeat treatment may be appropriate after a new exposure, accounting for ulipristal–progestogen interactions and copper-IUD suitability.

Levonorgestrel 1.5 mg oral (Postinor-1, Norlevo) :

Timeframe : Licensed for administration up to 72 hours (3 days) post-UPSI (efficacy declines rapidly over time; minimal efficacy between 72 and 120 hours).

Mechanism : Delays or inhibits ovulation by blunting the LH surge; ineffective once the LH surge has begun .

Body Weight Impact : Efficacy is significantly reduced in individuals weighing > 70 kg > 70\text{ kg} > 70 kg or with B M I > 30 kg/m 2 BMI > 30\text{ kg/m}^2 BM I > 30 kg/m 2 . In this cohort, Cu-IUD is first-line; if unavailable or declined, ulipristal is preferred. If levonorgestrel must be used, Australian guidelines recommend doubling the dose to 3 mg oral (two 1.5 mg tablets) .

Ongoing Contraception : Regular hormonal contraception can be started immediately ("quick-start") , requiring barrier protection for the next 7 days.

  • Pregnancy Termination in Australia
  • Legal Framework

Abortion has been decriminalized across all Australian States and Territories, transitioning termination of pregnancy from criminal law into mainstream public healthcare. Gestational limits for termination on request vary by state (generally up to 16 to 24 weeks' gestation). Beyond these statutory thresholds, termination requires clinical review and approval by two independent medical practitioners based on medical, physical, or psychosocial grounds. Healthcare practitioners with a conscientious objection are legally and ethically obligated to disclose their objection immediately and refer the patient without delay to an accessible, non-objecting practitioner or service.

Medical Termination of Pregnancy (MTOP)

In Australia, MTOP is approved and subsidized on the Pharmaceutical Benefits Scheme (PBS) under the MS-2 Step regimen for pregnancies up to 9 weeks (63 days) of gestation.

Step 1: Mifepristone 200 mg orally :

A potent synthetic competitive antiprogestogen with anti-glucocorticoid actions.

Binds uterine progesterone receptors, blocking progesterone action. This leads to decidual degeneration, detachment of the gestational sac, cervical softening, and sensitization of the myometrium to exogenous prostaglandins.

Step 2: Misoprostol 800 mcg buccally (36 to 48 hours later) :

A synthetic prostaglandin E 1 E_1 E 1 ​ analogue.

Stimulates powerful myometrial contractions and cervical dilatation, expelling the products of conception.

Clinical Course & Complications : Vaginal bleeding and uterine cramping typically begin 1 to 4 hours post-misoprostol, accompanied by the passage of blood clots and the gestational sac. Common self-limiting side effects include nausea, vomiting, diarrhoea, headache, chills, and transient low-grade fever ( < 38 ∘ C < 38^\circ\text{C} < 3 8 ∘ C ). Red-flag symptoms requiring urgent emergency assessment include soaking more than two maximal sanitary pads per hour for two consecutive hours, severe unremitting pelvic pain, foul-smelling vaginal discharge, or persistent fever ≥ 38 ∘ C \ge 38^\circ\text{C} ≥ 3 8 ∘ C lasting > 24 hours > 24\text{ hours} > 24 hours after misoprostol.

Completion follow-up: MS-2 Step product information requires review 14–21 days after mifepristone. Confirm completion with the agreed clinical, serum hCG or ultrasound pathway; earlier serum sampling can support this. Persistent pain, fever, heavy bleeding or ongoing pregnancy symptoms need earlier assessment.

Surgical Termination of Pregnancy (STOP)

In the first trimester, performed via suction aspiration curettage under local anaesthesia with conscious sedation or general anaesthesia. Preoperative cervical priming with misoprostol ( 400 mcg 400\text{ mcg} 400 mcg buccally 2 to 3 hours pre-procedure) softens the cervix and decreases procedural trauma.

In the second trimester, performed via dilatation and evacuation (D&E) or medical induction.

Abortion and anti-D: RANZCOG’s updated abortion guideline does not require routine RhD testing for medical or surgical abortion up to 10 weeks. Use current gestation-specific guidance after that point; 250 IU is not the correct dose for every gestation, and after 12 weeks the usual NBA dose is 625 IU. Miscarriage and ectopic pregnancy have separate prophylaxis indications.

Post-abortion contraception: Many methods can begin promptly. Giving DMPA on the mifepristone day may slightly increase ongoing-pregnancy risk, which should be explained; timing after misoprostol is another option. Follow-up includes the service’s low-sensitivity pregnancy-test or other completion protocol.

Clinical comparison: Comparison of Emergency Contraceptive Modalities

Mechanism : Copper Intrauterine Device (Cu-IUD): Sterile inflammatory reaction toxic to sperm; prevents fertilization & implantation; Ulipristal Acetate (EllaOne): Selective progesterone receptor modulator; delays LH surge and follicle rupture; Levonorgestrel (Postinor-1 / Norlevo): Progestogen; delays LH surge and follicle rupture only prior to onset of LH surge

Licensed Timeframe : Copper Intrauterine Device (Cu-IUD): Up to 120 hours (5 days) post-UPSI or 5 days post-ovulation; Ulipristal Acetate (EllaOne): Up to 120 hours (5 days) post-UPSI; Levonorgestrel (Postinor-1 / Norlevo): Up to 72 hours (3 days) post-UPSI

Comparative Efficacy : Copper Intrauterine Device (Cu-IUD): > 99.9 % > 99.9\% > 99.9% (highest of all methods); Ulipristal Acetate (EllaOne): High (superior to levonorgestrel); Levonorgestrel (Postinor-1 / Norlevo): Moderate; declines rapidly over time

Impact of High BMI : Copper Intrauterine Device (Cu-IUD): No reduction in efficacy ( B M I > 30 kg/m 2 BMI > 30\text{ kg/m}^2 BM I > 30 kg/m 2 ); Ulipristal Acetate (EllaOne): Maintained efficacy in overweight/obesity; Levonorgestrel (Postinor-1 / Norlevo): Reduced efficacy if weight > 70 kg > 70\text{ kg} > 70 kg or B M I > 30 BMI > 30 BM I > 30 (double dose to 3 mg)

Hormonal Quick-Start : Copper Intrauterine Device (Cu-IUD): Not applicable (non-hormonal); Ulipristal Acetate (EllaOne): Must wait 5 full days before starting hormonal contraception; Levonorgestrel (Postinor-1 / Norlevo): Can quick-start hormonal contraception immediately

Barrier Protection Period : Copper Intrauterine Device (Cu-IUD): None required (immediate ongoing contraception); Ulipristal Acetate (EllaOne): Condoms required for 12 days (5-day wait + 7 days of pills); Levonorgestrel (Postinor-1 / Norlevo): Condoms required for 7 consecutive days

Ongoing Contraception : Copper Intrauterine Device (Cu-IUD): Yes, provides 5 to 10 years of ongoing contraception; Ulipristal Acetate (EllaOne): No; provides no ongoing post-coital protection; Levonorgestrel (Postinor-1 / Norlevo): No; provides no ongoing post-coital protection

Primary references (checked 7 October 2026): Australian combined-pill flowchart ; RANZCOG abortion guideline .

MS-2 Step product information specifies the approved regimen and follow-up.